FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296992803> ?p ?o ?g. }

• W4296992803 endingPage "4604" @default.
• W4296992803 startingPage "4604" @default.
• W4296992803 abstract "Glioblastoma multiforme (GBM) is the most aggressive astrocytic primary brain tumor, and concurrent temozolomide (TMZ) and radiotherapy (RT) followed by maintenance of adjuvant TMZ is the current standard of care. Despite advances in imaging techniques and multi-modal treatment options, the median overall survival (OS) remains poor. As an alternative to surgery, re-irradiation (re-RT) can be a therapeutic option in recurrent GBM. Re-irradiation for brain tumors is increasingly used today, and several studies have demonstrated its feasibility. Besides differing techniques, the published data include a wide range of doses, emphasizing that no standard approach exists. The current study aimed to investigate the safety of moderate-high-voxel-based dose escalation in recurrent GBM. From 2016 to 2019, 12 patients met the inclusion criteria and were enrolled in this prospective single-center study. Retreatment consisted of re-irradiation with a total dose of 30 Gy (up to 50 Gy) over 5 days using the IMRT (arc VMAT) technique. A dose painting by numbers (DPBN)/dose escalation plan were performed, and a continuous relation between the voxel intensity of the functional image set and the risk of recurrence in that voxel were used to define target and dose distribution. Re-irradiation was well tolerated in all treated patients. No toxicities greater than G3 were recorded; only one patient had severe G3 acute toxicity, characterized by muscle weakness and fatigue. Median overall survival (OS2) and progression-free survival (PFS2) from the time of re-irradiation were 10.4 months and 5.7 months, respectively; 3-, 6-, and 12-month OS2 were 92%, 75%, and 42%, respectively; and 3-, 6-, and 12-month PFS2 were 83%, 42%, and 8%, respectively. Our work demonstrated a tolerable tolerance profile of this approach, and the future prospective phase II study will analyze the efficacy in terms of PFS and OS." @default.
• W4296992803 created "2022-09-25" @default.
• W4296992803 creator A5005796278 @default.
• W4296992803 creator A5006996702 @default.
• W4296992803 creator A5009102556 @default.
• W4296992803 creator A5009456362 @default.
• W4296992803 creator A5011742220 @default.
• W4296992803 creator A5013108855 @default.
• W4296992803 creator A5019735697 @default.
• W4296992803 creator A5020723280 @default.
• W4296992803 creator A5025457334 @default.
• W4296992803 creator A5034256771 @default.
• W4296992803 creator A5052225949 @default.
• W4296992803 creator A5064009671 @default.
• W4296992803 creator A5064977637 @default.
• W4296992803 creator A5067759067 @default.
• W4296992803 creator A5067784035 @default.
• W4296992803 creator A5078514785 @default.
• W4296992803 date "2022-09-22" @default.
• W4296992803 modified "2023-09-26" @default.
• W4296992803 title "Safety of Inhomogeneous Dose Distribution IMRT for High-Grade Glioma Reirradiation: A Prospective Phase I/II Trial (GLIORAD TRIAL)" @default.
• W4296992803 cites W1506994362 @default.
• W4296992803 cites W1860764269 @default.
• W4296992803 cites W1959628099 @default.
• W4296992803 cites W1967897018 @default.
• W4296992803 cites W1970188018 @default.
• W4296992803 cites W1970930921 @default.
• W4296992803 cites W1983418949 @default.
• W4296992803 cites W2008737433 @default.
• W4296992803 cites W2012769196 @default.
• W4296992803 cites W2020144249 @default.
• W4296992803 cites W2025799338 @default.
• W4296992803 cites W2026703672 @default.
• W4296992803 cites W2035722384 @default.
• W4296992803 cites W2038042304 @default.
• W4296992803 cites W2038869053 @default.
• W4296992803 cites W2042795314 @default.
• W4296992803 cites W2046279201 @default.
• W4296992803 cites W2048919807 @default.
• W4296992803 cites W2050272837 @default.
• W4296992803 cites W2050694970 @default.
• W4296992803 cites W2057290654 @default.
• W4296992803 cites W2063828422 @default.
• W4296992803 cites W2086372708 @default.
• W4296992803 cites W2087977626 @default.
• W4296992803 cites W2092016107 @default.
• W4296992803 cites W2092736872 @default.
• W4296992803 cites W2095365904 @default.
• W4296992803 cites W2096287682 @default.
• W4296992803 cites W2106264243 @default.
• W4296992803 cites W2110629578 @default.
• W4296992803 cites W2111137187 @default.
• W4296992803 cites W2112014411 @default.
• W4296992803 cites W2112584132 @default.
• W4296992803 cites W2118311655 @default.
• W4296992803 cites W2121396361 @default.
• W4296992803 cites W2127957020 @default.
• W4296992803 cites W2134609589 @default.
• W4296992803 cites W2135348205 @default.
• W4296992803 cites W2137686302 @default.
• W4296992803 cites W2137797918 @default.
• W4296992803 cites W2149594980 @default.
• W4296992803 cites W2160445648 @default.
• W4296992803 cites W2162643152 @default.
• W4296992803 cites W2162709266 @default.
• W4296992803 cites W2167571044 @default.
• W4296992803 cites W2170744163 @default.
• W4296992803 cites W2171150197 @default.
• W4296992803 cites W2260733053 @default.
• W4296992803 cites W2478972716 @default.
• W4296992803 cites W2566418305 @default.
• W4296992803 cites W2732147664 @default.
• W4296992803 cites W2753713884 @default.
• W4296992803 cites W2765814211 @default.
• W4296992803 cites W2767198352 @default.
• W4296992803 cites W2785443334 @default.
• W4296992803 cites W2793549603 @default.
• W4296992803 cites W2794618224 @default.
• W4296992803 cites W2902360852 @default.
• W4296992803 cites W2902487187 @default.
• W4296992803 cites W2902801574 @default.
• W4296992803 cites W2904710333 @default.
• W4296992803 cites W2945836601 @default.
• W4296992803 cites W2969542839 @default.
• W4296992803 cites W3002441166 @default.
• W4296992803 cites W3020099303 @default.
• W4296992803 cites W3031224726 @default.
• W4296992803 cites W3093513742 @default.
• W4296992803 cites W3146825663 @default.
• W4296992803 cites W3209846066 @default.
• W4296992803 cites W4210680179 @default.
• W4296992803 cites W4226359189 @default.
• W4296992803 cites W4232376350 @default.
• W4296992803 cites W4281397087 @default.
• W4296992803 cites W4292566582 @default.
• W4296992803 cites W4361868710 @default.
• W4296992803 doi "https://doi.org/10.3390/cancers14194604" @default.
• W4296992803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36230525" @default.

• next